Monitoring standard and extended half‐life products in hemophilia: Assay discrepancies for factor VIII and IX in pre‐ and postinfusion samples
Abstract Background Monitoring hemophilia treatment with extended half‐life products is challenging for coagulation laboratories since factor assays may show substantial differences between results obtained with the one‐stage assay (OSA) and the chromogenic substrate assay (CSA). Objectives The aim...
Main Authors: | Cecilia Augustsson, Eva Norström, Nadine Gretenkort Andersson, Eva Zetterberg, Jan Astermark, Karin Strandberg |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-10-01
|
Series: | Research and Practice in Thrombosis and Haemostasis |
Subjects: | |
Online Access: | https://doi.org/10.1002/rth2.12421 |
Similar Items
-
Impact of novel hemophilia therapies around the world
by: Margareth C. Ozelo, et al.
Published: (2022-03-01) -
Clinical and Laboratory Approaches to Hemophilia A
by: Hassan Mansouritorghabeh
Published: (2015-05-01) -
Strategies for Hemophilia Treatment, a literature review of current evidence
by: Fahimeh Ghasemi, et al.
Published: (2023-12-01) -
Chinese Expert Consensus on Pharmacokinetics Guided Treatment for Hemophilia A
by: Hemophilia Treatment Center Collaborative Network of China
Published: (2022-10-01) -
“Prevalence of Inhibitors in Hemophilia Patients and its Clinical Implications”: A Study of 276 Patients in Western India
by: Sangita Darshan Shah, et al.
Published: (2019-01-01)